SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2023.
“As announced on November 2, we are thrilled to welcome Chas McKhann as the new Chief Executive Officer of Silk Road Medical,” said Jack Lasersohn, Chairman of the Board of Directors. “Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets. We believe he is the right leader to leverage our strong infrastructure, skilled commercial team, and substantial body of clinical evidence to drive further TCAR adoption.”
Third Quarter 2023 Financial Results
Revenue for the third quarter of 2023 was $44.4 million, an increase of $7.1 million or 19%, compared to the third quarter of 2022. Growth was driven primarily by increased TCAR adoption.
Gross profit for the third quarter of 2023 was $32.4 million compared to $28.1 million for the third quarter of 2022. Gross margin was 73% for the third quarter of 2023 compared to 75% for the third quarter of 2022. The decrease was driven by a revaluation of standard costs in the prior year period which benefitted margins, as well as higher manufacturing costs associated with having two manufacturing facilities fully operational in the third quarter of 2023.
Operating expenses were $46.1 million for the third quarter of 2023, compared to $37.3 million in the comparable prior year period, which represents an increase of 24%. The increase was due primarily to the continued expansion of the sales team and commercial efforts.
Net loss was $12.8 million in the third quarter of 2023, or $0.33 per share, as compared to a loss of $10.3 million, or $0.29 per share, in the corresponding period of the prior year.
Cash, cash equivalents and investments were $197.2 million as of September 30, 2023.
2023 Financial Guidance
Silk Road Medical projects revenue for full year 2023 to range from $170 million to $174 million, which represents 23% to 26% growth over the Company’s prior year revenue.
Conference Call
Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss its third quarter 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995, including Silk Road Medical’s financial guidance. Forward-looking statements are based on current expectations of future events and often can be identified by words such as “expect,” “should,” “project,” “anticipate,” “intend,” “will,” “can,” “may,” “believe,” “could,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause Silk Road Medical’s actual results to be materially different than those expressed in or implied by Silk Road Medical’s forward-looking statements. For Silk Road Medical, such risks and uncertainties include, among others, future operating results and financial performance; risks surrounding the CEO transition; the Company’s success in retaining and recruiting key personnel; the ability to continue to grow the business and expand the use of TCAR; the ability to obtain an adequate supply of materials and components from its third-party suppliers; product development plans and the ability to commercialize new products in a timely manner; the success of current clinical trials; plans to conduct further clinical trials; the ability to obtain additional indications or new regulatory approvals or clearances for its products; market acceptance and use of its products by physicians; the ability to grow and leverage its commercialization infrastructure; increased competition; the effect of economic conditions and COVID-19 or similar pandemics on its business; government and third-party payer coverage and reimbursement and the ability to obtain and maintain intellectual property protection for its products. More detailed information on these and other factors that could affect Silk Road Medical’s actual results are described in its filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023. Silk Road Medical undertakes no obligation to update its forward-looking statements.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
investors@silkroadmed.com
Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com
| SILK ROAD MEDICAL, INC. | ||||||||||||||||
| Statements of Operations Data | ||||||||||||||||
| (unaudited, in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 44,435 | $ | 37,374 | $ | 129,864 | $ | 98,567 | ||||||||
| Cost of goods sold | 12,050 | 9,308 | 37,580 | 26,897 | ||||||||||||
| Gross profit | 32,385 | 28,066 | 92,284 | 71,670 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 10,047 | 8,471 | 31,260 | 27,249 | ||||||||||||
| Selling, general and administrative | 36,009 | 28,821 | 105,923 | 83,795 | ||||||||||||
| Total operating expenses | 46,056 | 37,292 | 137,183 | 111,044 | ||||||||||||
| Loss from operations | (13,671 | ) | (9,226 | ) | (44,899 | ) | (39,374 | ) | ||||||||
| Interest income | 2,617 | 617 | 7,339 | 751 | ||||||||||||
| Interest expense | (1,732 | ) | (1,714 | ) | (5,137 | ) | (3,366 | ) | ||||||||
| Loss on debt extinguishment | — | — | — | (245 | ) | |||||||||||
| Other income (expense), net | (2 | ) | 4 | (35 | ) | (162 | ) | |||||||||
| Net loss | (12,788 | ) | (10,319 | ) | (42,732 | ) | (42,396 | ) | ||||||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized gain (loss) on investments, net | 47 | (189 | ) | (118 | ) | (191 | ) | |||||||||
| Other comprehensive loss | 47 | (189 | ) | (118 | ) | (191 | ) | |||||||||
| Net loss and comprehensive loss | $ | (12,741 | ) | $ | (10,508 | ) | $ | (42,850 | ) | $ | (42,587 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.33 | ) | $ | (0.29 | ) | $ | (1.10 | ) | $ | (1.21 | ) | ||||
| Weighted average common shares used to compute net loss per share, basic and diluted | 38,865,011 | 35,303,958 | 38,722,012 | 35,157,840 | ||||||||||||
| SILK ROAD MEDICAL, INC. | |||||||
| Balance Sheets Data | |||||||
| (unaudited, in thousands) | |||||||
| September 30, 2023 | December 31, 2022 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 29,188 | $ | 55,358 | |||
| Short-term investments | 163,673 | 158,316 | |||||
| Accounts receivable, net | 21,779 | 18,007 | |||||
| Inventories | 22,066 | 19,293 | |||||
| Prepaid expenses and other current assets | 4,277 | 3,924 | |||||
| Total current assets | 240,983 | 254,898 | |||||
| Long-term investments | 4,348 | — | |||||
| Property and equipment, net | 8,337 | 9,372 | |||||
| Restricted cash | — | 155 | |||||
| Other non-current assets | 7,196 | 5,260 | |||||
| Total assets | $ | 260,864 | $ | 269,685 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 5,094 | $ | 2,523 | |||
| Accrued liabilities | 18,928 | 21,965 | |||||
| Total current liabilities | 24,022 | 24,488 | |||||
| Long-term debt | 75,364 | 74,596 | |||||
| Other liabilities | 8,336 | 6,726 | |||||
| Total liabilities | 107,722 | 105,810 | |||||
| Stockholders' equity | |||||||
| Preferred stock, $0.001 par value | — | — | |||||
| Common stock, $0.001 par value | 39 | 38 | |||||
| Additional paid-in capital | 539,831 | 507,715 | |||||
| Accumulated other comprehensive loss | (284 | ) | (166 | ) | |||
| Accumulated deficit | (386,444 | ) | (343,712 | ) | |||
| Total stockholders' equity | 153,142 | 163,875 | |||||
| Total liabilities and stockholders' equity | $ | 260,864 | $ | 269,685 | |||
